Faces Medicaid attrition risk where the remaining pool of insured members is sicker, posing a risk to future earnings.

The regulatory re-rating provides a fundamental floor for value-based healthcare providers.

Suffering from Medicaid redetermination crisis and sicker patient base; analyst suggests waiting until mid-2027 for a potential entry point.

Reported 'disastrous' results, missing expectations 'everywhere' with a 'terrible' earnings trajectory. 2025 earnings are expected to be down 51%.

Part of the worst-performing healthcare subsector (medical insurance) due to higher-than-expected cost increases; the stock was down 42%.

Stock was down 4% due to the delayed vote on extending ACA subsidies, creating a short-term headwind for the sector.

Reported 'awful' results, missing earnings by a wide margin and drastically reducing its 2025 earnings guidance by 26%. The stock fell 20% on the news.

A bullish short-term signal was generated by the speaker's quantitative trading tool, indicating a short-term trade opportunity.

Stock is down significantly (in the 40% to 53% range) due to 'absolute carnage' in the managed care sector from rising healthcare costs.

Identified as a clear loser from the new bill, which includes major cuts to Medicaid, directly threatening the company's revenue and growth prospects.